Still a solid source of exposure to its target sector. Hartford Healthcare remains in good hands after several personnel changes in recent years, while its well-established and appealing approach remains intact. The strategy retains its People and Process Pillar ratings of Above Average.
Hartford Healthcare HLS Fund Class IB HBGHX
- NAV / 1-Day Return 16.36 / −1.22 %
- Total Assets 111.8M
-
Adj. Expense Ratio
1.190%
- Expense Ratio 1.190%
- Distribution Fee Level High
- Share Class Type Institutional
- Category Health
- Investment Style Large Value
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.46%
- Turnover 50%
USD | NAV as of Jul 20, 2026 | 1-Day Return as of Jul 20, 2026, 9:23 PM GMT+0
Morningstar’s Analysis HBGHX
Will HBGHX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 47.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 12.67 | 13M | Healthcare |
Merck & Co Inc | 6.70 | 7M | Healthcare |
Johnson & Johnson | 5.60 | 6M | Healthcare |
UnitedHealth Group Inc | 4.89 | 5M | Healthcare |
Intuitive Surgical Inc | 3.39 | 4M | Healthcare |
Elevance Health Inc | 3.20 | 3M | Healthcare |
AbbVie Inc | 3.15 | 3M | Healthcare |
Abbott Laboratories | 2.77 | 3M | Healthcare |
Danaher Corp | 2.70 | 3M | Healthcare |
CVS Health Corp | 2.62 | 3M | Healthcare |
United States